Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Clozapine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 10/20 | 1.00 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 9/20 | 1.00 |
| ▸ | DRD4 | P21917 | 7/20 | 1.00 |
| ▸ | DRD1 | P21728 | 4/20 | 1.00 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 1.00 |
| ▸ | DRD3 | P35462 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 2/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | CHRM3 | P20309 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | CACNA1F | O60840 | 1/20 | 1.00 |
| ▸ | HTR3B | O95264 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clozapine SCHEMBL8397 | 1.00 | DRD2 (1.00) | DRD2CHRM1DRD4DRD1HRH4 | |
| Clozapine SCHEMBL20876213 | 1.00 | DRD2 (1.00) | DRD2CHRM1DRD4DRD1HRH4 | |
| Clozapine SCHEMBL5501558 | 1.00 | DRD2 (1.00) | DRD2CHRM1DRD4DRD1HRH4 | |
| Clozapine SCHEMBL29590817 | 1.00 | DRD2 (1.00) | DRD2CHRM1DRD4DRD1HRH4 | |
| Clozapine SCHEMBL29433929 | 1.00 | DRD2 (1.00) | DRD2CHRM1DRD4DRD1HRH4 | |
| Clozapine SCHEMBL28700741 | 0.99 | DRD2 (0.98) | DRD2CHRM1DRD4DRD1HRH4 | |
| Clozapine SCHEMBL28648626 | 0.99 | DRD2 (0.98) | DRD2CHRM1DRD4DRD1HRH4 | |
| Clozapine SCHEMBL29180214 | 0.99 | DRD2 (0.98) | DRD2CHRM1DRD4DRD1HRH4 | |
| Clozapine SCHEMBL140458 | 0.99 | DRD2 (0.98) | DRD2CHRM1DRD4DRD1HRH4 | |
| Clozapine SCHEMBL29041024 | 0.99 | DRD2 (0.98) | DRD2CHRM1DRD4DRD1HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 134 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025078446-A1 | MICROFLUIDIC DEVICE AND METHOD THEREOF FOR RAPID ASSAYS IN SAMPLES | OLSSON CARL (SE) | 2025-04-17 | — | — | WO | claimed |
| WO-2024249914-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING DYSTONIA | DUKE UNIVERSITY (US) | 2024-12-05 | — | — | WO | claimed |
| US-20240173277-A1 | ANTI-MYCOBACTERIAL DRUGS | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2024-05-30 | — | — | US | claimed |
| US-11974972-B1 | Anti-mycobacterial drugs | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2024-05-07 | — | — | US | claimed |
| US-20240000732-A1 | ANTI-MYCOBACTERIAL DRUGS | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2024-01-04 | — | — | US | claimed |
| US-11857521-B1 | Anti-mycobacterial drugs | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2024-01-02 | — | — | US | claimed |
| US-20260104380-A1 | GOLD-COATED MICRO-CHIP CLOZAPINE SENSOR FUNCTIONALIZED WITH CYZ NANOSHEET | KING ABDULAZIZ UNIVERSITY (SA) | 2026-04-16 | — | — | US | disclosed |
| US-20260083759-A1 | Combinations Comprising Psychedelics for the Treatment of Schizophrenia and Other Neuropsychiatric and Neurologic Disorders | HADASIT MED RES SERVICE (IL) | 2026-03-26 | — | — | US | disclosed |
| US-12558362-B2 | Use of cannabidiol in the treatment of seizures associated with rett syndrome | JAZZ PHARMACEUTICALS RESEARCH UK LIMITED (GB) | 2026-02-24 | — | — | US | disclosed |
| US-12558366-B2 | Bacterial DNA gyrase inhibitors and methods of use thereof | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2026-02-24 | — | — | US | disclosed |
| EP-4180799-B1 | METHOD OF CLASSIFYING MILK | PPB TECH PTY LTD (AU) | 2025-12-24 | — | — | EP | disclosed |
| EP-4661017-A1 | MENTAL ILLNESS DIAGNOSIS AND DRUG RECOMMENDATION METHOD | Samsung Life Public Welfare Foundation (KR) | 2025-12-10 | — | — | EP | disclosed |
| US-20250372199-A1 | ALLELIC IMBALANCE OF CHROMATIN ACCESSIBILITY IN CANCER IDENTIFIES CAUSAL RISK VARIANTS AND THEIR MECHANISMS | DANA FARBER CANCER INST INC (US) | 2025-12-04 | — | — | US | disclosed |
| WO-2022056475-A1 | COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING A DYSTONIA | DUKE UNIVERSITY (US) | 2022-03-17 | — | — | WO | disclosed |
| CN-114051417-A | Drug dissolution type stent | 大塚医疗器械有限公司 | 2022-02-15 | — | — | CN | disclosed |
| EP-3946302-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | Apkarian Technologies LLC (US) | 2022-02-09 | — | — | EP | disclosed |
| US-11241388-B2 | Multiple unit dosage form having a therapeutic agent in combination with a nutritional supplement | JDS THERAPEUTICS, LLC (US) | 2022-02-08 | — | — | US | disclosed |
| US-20220026427-A1 | CELL BASED ASSAYS AND KITS FOR ASSESSING SERUM CHOLINERGIC RECEPTOR ACTIVITY | CENTRE FOR ADDICTION AND MENTAL HEALTH (CA) | 2022-01-27 | — | — | US | disclosed |
| WO-2022017927-A1 | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH PERISYLVIAN FISSURE SYNDROME | GW Research Limited (GB) | 2022-01-27 | — | — | WO | disclosed |
| WO-2022017937-A1 | USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RETT SYNDROME | GW Research Limited (GB) | 2022-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083759-A1 | Combinations Comprising Psychedelics for the Treatment of Schizophrenia and Other Neuropsychiatric and Neurologic Disorders | BDNF, NTRK2, GRIN2A | DRD2 32/4885HTR2A 33/4885CHRM1 64/4885 |
| US-12558362-B2 | Use of cannabidiol in the treatment of seizures associated with rett syndrome | CNR2, CNR1, RET | DRD2 55/4885HTR2A 1407/4885CHRM1 406/4885 |
| US-11241388-B2 | Multiple unit dosage form having a therapeutic agent in combination with a nutritional supplement | SLC5A6, SLC19A1, SLC25A20 | DRD2 4335/4885HTR2A 3022/4885CHRM1 3969/4885 |
| US-20240173277-A1 | ANTI-MYCOBACTERIAL DRUGS | OAT, OGA, OTC | DRD2 2437/4885HTR2A 3700/4885CHRM1 1239/4885 |
| US-11974972-B1 | Anti-mycobacterial drugs | OAT, OGA, OTC | DRD2 2437/4885HTR2A 3700/4885CHRM1 1239/4885 |
| US-11857521-B1 | Anti-mycobacterial drugs | OAT, OGA, OTC | DRD2 2437/4885HTR2A 3700/4885CHRM1 1239/4885 |
| US-20260104380-A1 | GOLD-COATED MICRO-CHIP CLOZAPINE SENSOR FUNCTIONALIZED WITH CYZ NANOSHEET | WIZ, ZKSCAN2, YWHAZ | DRD2 179/4885HTR2A 1123/4885CHRM1 254/4885 |
| US-12558366-B2 | Bacterial DNA gyrase inhibitors and methods of use thereof | DNA2, TOP2A, TOP2B | DRD2 2855/4885HTR2A 314/4885CHRM1 4745/4885 |
| US-20240000732-A1 | ANTI-MYCOBACTERIAL DRUGS | OAT, OGA, OTC | DRD2 2437/4885HTR2A 3700/4885CHRM1 1239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.